Werewolf Therapeutics Inc HOWL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Are MKTX, HOWL, PSNL Obtaining Fair Deals for their Shareholders?
-
Are PSNL, MKTX, BZH, HOWL Obtaining Fair Deals for their Shareholders?
-
HOWL Stock Alert: Halper Sadeh LLC is Investigating Whether Werewolf Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders
-
$HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the Merger - HOWL, HZO, TYFG and FULC
-
Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 Million Private Placement
-
Werewolf Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
Trading Information
- Previous Close Price
- $1.00
- Day Range
- $0.97–1.01
- 52-Week Range
- $0.27–1.83
- Bid/Ask
- $0.98 / $0.98
- Shares Outstanding
- 48.60M
- Market Cap
- $47.63M
- Volume/Avg
- 309,249 / 7M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.27
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 14
- Website
- https://www.werewolftx.com
Valuation
|
Metric
|
HOWL
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.92 |
Price/Sales | 2.27 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
HOWL
|
|---|---|
Quick Ratio | 2.80 |
Current Ratio | 2.91 |
Interest Coverage | −7.04 |
Quick Ratio
HOWL
Profitability
|
Metric
|
HOWL
|
|---|---|
Return on Assets (Normalized) | −46.41% |
Return on Equity (Normalized) | −120.81% |
Return on Invested Capital (Normalized) | −50.10% |
Return on Assets
HOWL
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|qNHm&y? | LOCK|lb>!q | $127B | |||
| Moderna Inc
MRNA
| LOCK|lyTQkfd | LOCK|&f | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|Dtn>MG | LOCK|%<y& | $81B | |||
| argenx SE ADR
ARGX
| LOCK|W??DwG# | LOCK|!>d | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|H%>#%P | LOCK|?% | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|Ht^c>< | LOCK|!!$w& | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|Y%DYJJh | LOCK|%P$^% | $27B | |||
| Incyte Corp
INCY
| LOCK|YnRzZw | LOCK|Nr | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|&fLQP@& | LOCK|Xm | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|Cv>MlNJ | LOCK|Z^ | $14B |
United States